File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Polypoidal choroidal vasculopathy in Canada

TitlePolypoidal choroidal vasculopathy in Canada
Authors
Issue Date2020
PublisherElsevier for the Canadian Ophthalmological Society. The Journal's web site is located at http://www.canadianjournalofophthalmology.ca
Citation
Canadian Journal of Ophthalmology, 2020, v. 55, p. 199-211 How to Cite?
AbstractPolypoidal choroidal vasculopathy (PCV) is an exudative age-related macular degeneration (AMD) subtype found more frequently among Asians than Caucasians. If untreated, it may lead to severe vision loss. PCV appears to be frequently underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made on the basis of multimodal imaging, including optical coherence tomography (OCT) and OCT angiography combined with colour fundus photography, or by other imaging techniques; the gold-standard indocyanine green angiography (ICGA) is not widely used in Canada. Treatment involves anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in combination with photodynamic therapy (PDT). Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/295762
ISSN
2020 Impact Factor: 1.882
2015 SCImago Journal Rankings: 0.685
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, WC-
dc.contributor.authorChoudhry, N-
dc.contributor.authorWong, D-
dc.date.accessioned2021-02-08T08:13:39Z-
dc.date.available2021-02-08T08:13:39Z-
dc.date.issued2020-
dc.identifier.citationCanadian Journal of Ophthalmology, 2020, v. 55, p. 199-211-
dc.identifier.issn0008-4182-
dc.identifier.urihttp://hdl.handle.net/10722/295762-
dc.descriptionHybrid open access-
dc.description.abstractPolypoidal choroidal vasculopathy (PCV) is an exudative age-related macular degeneration (AMD) subtype found more frequently among Asians than Caucasians. If untreated, it may lead to severe vision loss. PCV appears to be frequently underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made on the basis of multimodal imaging, including optical coherence tomography (OCT) and OCT angiography combined with colour fundus photography, or by other imaging techniques; the gold-standard indocyanine green angiography (ICGA) is not widely used in Canada. Treatment involves anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in combination with photodynamic therapy (PDT). Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT.-
dc.languageeng-
dc.publisherElsevier for the Canadian Ophthalmological Society. The Journal's web site is located at http://www.canadianjournalofophthalmology.ca-
dc.relation.ispartofCanadian Journal of Ophthalmology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePolypoidal choroidal vasculopathy in Canada-
dc.typeArticle-
dc.identifier.emailLam, WC: waichlam@hku.hk-
dc.identifier.authorityLam, WC=rp02162-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.jcjo.2019.10.011-
dc.identifier.pmid31879067-
dc.identifier.hkuros321095-
dc.identifier.volume55-
dc.identifier.spage199-
dc.identifier.epage211-
dc.identifier.isiWOS:000540442800017-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats